Dr Rachel Orme

  • MBChB, MD, MRCP
  • Cardiologist
  • Spoken languages English

Overview

I knew Cardiology was the specialty for me, the wide range of treatment options available really have a positive impact on individual patients.

Specialises in chest pain, acute coronary syndromes, coronary intervention and cardiac rehabilitation.

Dr Rachel Orme is an interventional and general cardiologist who completed her training and worked as a consultant cardiologist at a large tertiary teaching hospital in Sheffield (UK) before relocating to the South West.

Rachel has a comprehensive background including experience and training in the diagnosis, treatment and management of Ischaemic Heart Disease, Heart failure, Cardiac Rhythm Management, Pregnancy and Heart Disease, Inherited Cardiac Conditions and Adult Congenital Heart Disease.

Rachel has broad experience in the management of primary, acute and elective percutaneous coronary intervention. Her research interests are in the medications used in the management of coronary artery disease treated by angioplasty.

Rachel has been particularly involved in cardiac rehabilitation following Acute Coronary Syndromes and the management of peri-infarct and post-infarct heart failure, secondary prevention and guiding the duration of antiplatelet therapy in individual patients according to their risk factors and coronary anatomy.

Research interests

Study of medications used in the management of patients with coronary artery disease undergoing percutaneous coronary intervention.

Professional memberships

  • Membership of the Royal College of Physicians (UK) (MRCP)

Publications and affiliations

  • Prolonged enoxaparin therapy compared with standard-of-care antithrombotic therapy in opiate-treated patients undergoing primary percutaneous coronary intervention. Sumaya W, Parker WAE, Judge HM, Hall IR, Orme RC, Adam Z, Richardson JD, Rothman AMK, Morgan KP, Gunn JP, Storey RF. Platelets. 2020 Jun 16:1-5. doi: 10.1080/09537104.2020.1779925.
  • Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. Parker WAE, Orme RC, Hanson J, Stokes HM, Bridge CM, Shaw PA, Sumaya W, Thorneycroft K, Petrucci G, Porro B, Judge HM, Ajjan RA, Rocca B, Storey RF. Platelets. 2019;30(2):148-157. doi: 10.1080/09537104.2019.1572880.
  • Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI) Orme RC, Parker WAE, Thomas MR et al. Circulation June 2018.
  • Monitoring Antiplatelet Therapy, Orme R, Judge HM, Storey RF, Seminars in Thrombosis and Haemostasis 2016.